Exhibit 99.1
DBV Technologies Announces Appointment of Michel de Rosen as
Non-Executive
Chairman of the Board of Directors
Mr. de Rosen to succeed DBVs
co-founder,
Dr. Pierre-Henri Benhamou, who will retire from the Board of Directors and join Scientific Advisory Board
Chief Executive Officer, Daniel
Tassé, has also been appointed to the Board of Directors
DBV Technologies (Euronext: DBV ISIN: FR0010417345Nasdaq Stock Market:
DBVT), a clinical-stage biopharmaceutical company, today announced that the Board of Directors has appointed existing board member, Michel de Rosen, as
Non-Executive
Chairman of the Board. Mr. de Rosen
succeeds DBV Technologies
co-founder,
Dr. Pierre-Henri Benhamou, who retired from his position as DBVs
Non-Executive
Chairman and board member.
Dr. Benhamou will join the Companys Scientific Advisory Board, effective immediately. Additionally, Daniel Tassé, Chief Executive Officer of DBV Technologies, has been appointed to the Board, replacing Dr. Pierre-Henri
Benhamou. With these changes, effective immediately, DBVs Board consists of eight directors.
On behalf of DBVs Board, I would like
to thank Pierre-Henri for his leadership and ongoing commitment to this organization. We also welcome Daniel, as well as Michel and his expanded role, and look forward to our continued partnership in building a leading biopharmaceutical
company,
said
Dr.
Torbjörn Bjerke, DBV Technologies
Board Director
.
Mr. de Rosen has served on DBVs Board of Directors since June 2018.
He is currently Chairman of the Board of Faurecia, a global supplier of
automotive equipment, and Chairman of the Board of Pharnext, a publicly-traded pharmaceutical company. Previously, he served as Chairman and Chief Executive Officer of Eutelsat, Chairman and Chief Executive Officer of ViroPharma and Chairman and
Chief Executive Officer of
Rhône-Poulenc
Santé. Earlier in his career, Michel de Rosen held key positions at the French Ministries of Finance, Defense, Industry, and Telecommunications.